Macitentan API Manufacturer in India

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Macitentan API

Macitentan is an orally active endothelin receptor antagonist (ERA) used primarily in the treatment of pulmonary arterial hypertension (PAH). It blocks the effects of endothelin-1, a potent vasoconstrictor involved in vascular smooth-muscle proliferation and remodeling.

Macitentan selectively targets endothelin ETA and ETB receptors and is designed to provide sustained blockade of the endothelin pathway.

Macitentan API Manufacturer in India

Macitentan is a specialized cardiovascular pharmaceutical API used in the development and manufacture of oral formulations for pulmonary arterial hypertension.

Important API quality attributes include identity, assay, related substances, water content, residue on ignition, residual solvents, elemental impurities and polymorphic characteristics.

Chemical Information

CAS Number: 441798-33-0
Molecular Formula: C19H20Br2N6O4S
Molecular Weight: 588.28 g/mol
Chemical Name: N-[5-(4-bromophenyl)-6-[2-[(5-bromopyrimidin-2-yl)oxy]ethoxy]pyrimidin-4-yl]-N'-propylsulfamide
Drug Class: Endothelin Receptor Antagonist
Therapeutic Class: Pulmonary Antihypertensive
Therapeutic Area: Cardiovascular / Pulmonology
Molecule Type: Synthetic Small Molecule

Mechanism of Action

Macitentan blocks endothelin receptors, inhibiting the activity of endothelin-1.

Its pharmacological activity includes:

  • ETA receptor antagonism
  • ETB receptor antagonism
  • Reduction of endothelin-mediated vasoconstriction
  • Reduction of vascular smooth-muscle proliferation
  • Reduction of pulmonary vascular resistance
  • Modulation of pulmonary vascular remodeling

By inhibiting the endothelin pathway, Macitentan helps reduce the excessive vasoconstrictive and proliferative signaling associated with pulmonary arterial hypertension.

Pharmaceutical Applications

Macitentan API is used in pharmaceutical formulations for:

  • Pulmonary arterial hypertension
  • PAH associated with connective tissue disease
  • Pulmonary vascular disease research
  • Endothelin receptor research
  • Cardiovascular drug development
  • Pulmonary hypertension drug development

Cardiovascular Applications

Macitentan is particularly relevant to pulmonary arterial hypertension, where abnormal endothelin signaling contributes to narrowing and remodeling of pulmonary blood vessels.

Its dual endothelin-receptor activity makes it an important pharmaceutical compound for pulmonary vascular disease management and research.

Physical Characteristics

Macitentan is generally described as a white to off-white solid/crystalline powder. Its physicochemical properties should be characterized according to the applicable API specification and formulation requirements.

Manufacturing Process

A controlled Macitentan API manufacturing process may involve:

  1. Preparation of qualified starting materials
  2. Synthesis of substituted pyrimidine intermediates
  3. Introduction of bromophenyl and bromopyrimidine groups
  4. Ether-linkage formation
  5. Sulfamide formation
  6. Purification
  7. Crystallization or isolation
  8. Filtration
  9. Controlled drying
  10. Milling, where required
  11. Final analytical testing
  12. GMP-compliant packaging

Quality Control Testing

Typical Macitentan API testing may include:

  • Identification by IR
  • HPLC identification
  • Assay by HPLC
  • Related substances
  • Degradation products
  • Water content
  • Residual solvents
  • Elemental impurities
  • Polymorphic form
  • Particle-size distribution, where applicable
  • Stability testing

Storage

Store Macitentan API in a tightly closed container under controlled pharmaceutical storage conditions, protected from excessive heat, moisture and direct light. Final storage conditions should follow validated stability data and the manufacturer's approved specification.

Pharmaceutical Research

Macitentan is relevant to research involving:

  • Endothelin-1 signaling
  • ETA receptors
  • ETB receptors
  • Pulmonary arterial hypertension
  • Pulmonary vascular remodeling
  • Pulmonary hypertension
  • Cardiovascular pharmacology
  • Endothelin receptor antagonists
  • Pulmonary drug development

Detailed Specifications

Parameter Specification
Appearance White to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Heavy Metals NMT 10 ppm
pH (1% Solution) 2.0 – 4.0
Individual Impurity NMT 0.5%
Total Impurities NMT 1.0%
Water Content NMT 1.0%
Get Bulk Quote via WhatsApp